Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Mesenchymal Stem Cell Transplantation in the Treatment of Chronic Allograft Nephropathy

The recruitment status of this study is unknown because the information has not been verified recently.
Verified April 2008 by Organ Transplant Institute, China.
Recruitment status was  Not yet recruiting
Information provided by:
Organ Transplant Institute, China Identifier:
First received: April 14, 2008
Last updated: NA
Last verified: April 2008
History: No changes posted

April 14, 2008
April 14, 2008
May 2008
May 2008   (final data collection date for primary outcome measure)
Creatinine and creatinine clearance rate [ Time Frame: 5 ] [ Designated as safety issue: Yes ]
Same as current
No Changes Posted
  • Patient and graft survival [ Time Frame: At 1 years post-transplant ]. [ Time Frame: 5 ] [ Designated as safety issue: Yes ]
  • The proportion of renal biopsy after 12 months [ Time Frame: 2 ] [ Designated as safety issue: Yes ]
  • The incidence of infectious complications [ Time Frame: 5 ] [ Designated as safety issue: Yes ]
  • Incidence of adverse events associated with MSC and immunosuppression [ Time Frame: 5 ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
Mesenchymal Stem Cell Transplantation in the Treatment of Chronic Allograft Nephropathy
Mesenchymal Stem Cell Transplantation in the Treatment of Chronic Allograft Nephropathy

Mesenchymal Stem Cell (MSC) have been shown to have immunosuppressive and repairing properties. the investigators will infuse expanded MSC into patients who develop Chronic Allograft Nephropathy. The purpose of this study is to find out MSC is more effective in preventing organ rejection and maintaining kidney function.

Kidney transplantation is a common procedure in hospitals, but organ rejection and chronic nephrotoxicity are potential problems for the patient. Approximately ninety percent of the protocol biopsies of renal allografts, performed at 18 months post transplantation, show histological lesions of chronic calcineurin nephrotoxicity. Mesenchymal Stem Cell (MSC) has been shown to have immunosuppressive and repairing properties. Some patient in this study will also receive two infusions of expanded MSC. This study will evaluate the safety and effectiveness of MSC infusions in patients .

This study will last 2 years. Participants will be randomly assigned to receive either the full immunosuppressive therapy and MSC infusions (Group 1) or immunosuppressive therapy alone (Group 2). Patients will undergo MSC infusions at the start of the study on Day 0. One year post- infusions, patients will be evaluated. At Months 12 participants will undergo kidney biopsies. Blood collection will occur at regular intervals, Serum creatinine and the estimated creatinine clearance will be monthly recorded. The transplanted kidney function will be evaluated.

Phase 1
Phase 2
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Kidney Transplant
  • Chronic Allograft Nephropathy
Biological: mesenchymal stem cell
transplantation of mesenchymal stem cell
Other Name: MMF FK506
Experimental: 1
transplantation of mesenchymal stem cell
Intervention: Biological: mesenchymal stem cell
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Not yet recruiting
May 2010
May 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Recipients of a renal allograft, Male and female patients age 18 to 60 years of age.
  • Ability to provide written informed consent.
  • The serum creatinine form 176umol/L(2mg/ml) to 440umol/L(5mg/ml)
  • Renal biopsy Criteria: chronic allograft nephropathy (Banff I-II).
  • Immunosuppressant:CNI and MMF and Sirolimus
  • Written informed consent, compliant with local regulations.

Exclusion Criteria:

  • Recipients with leucopenia (WBC < 3000/mm³), thrombocytopenia (Thr < 100.000/mm³),or hyperlipidemia (Tot Chol > 300 mg/dl or Triglycerides > 300 mg/dl).
  • Recipients of multiple organs.
  • Pregnant women.
  • Previous history of malignancy
  • Active infection including hepatitis B, hepatitis C, HIV, or TB as determined by a positive skin test or clinical presentation, or under treatment for suspected TB.
  • Evidence of cardiovascular disease, existing congestive cardiac failure on physical exam and/or acute coronary syndrome in past 6 months.
  • Inadequate compliance to treatment.
18 Years to 60 Years
Contact: Jianming Tan T Jianming, Professor 008613375918000 DOCTORTJM@YAHOO.COM
Contact: Junqi Guo G Junqi, vicProfessor 008613960941458
fuzhough0712, fuzhough0712
Fuzhou General Hospital
Not Provided
Principal Investigator: Jianming Tan T Jianming, professor Fuzhou General Hospital
Organ Transplant Institute, China
April 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP